OKUR · OnKure Therapeutics, Inc.

OnKure Therapeutics reported its first quarter 2026 financial results, reflecting a strategic pivot toward next-generation PI3Kα pan-mutant inhibitors. The company ended the quarter with $192.1 million in cash and cash equivalents, bolstered by a $150 million private placement that closed on March 31, 2026. This capital is expected to fund operations into 2029, providing a multi-year runway to advance key programs. Research and development expenses decreased to $11.7 million from $13.0 million in the prior year quarter, primarily due to lower outsourced R&D costs, partially offset by increased clinical trial expenses. General and administrative expenses were relatively flat at $3.9 million. Net loss narrowed to $15.2 million ($1.11 per share) from $15.9 million ($1.19 per share) in Q1 2025. Operationally, OnKure announced the nomination of two development candidates: OKI-355 for vascular anomalies and OKI-345 for breast cancer, both designed as selective PI3Kα pan-mutant inhibitors with potential for wider therapeutic index. IND submissions for both candidates are planned for the first half of 2027. The company also initiated a discovery research program in vascular anomalies. In contrast, OnKure is not planning to independently pursue further clinical development of its earlier-stage mutant-specific inhibitor OKI-219, though it will report data from the PIKture-01 trial by end of 2026. Management commentary emphasized a sharpened strategic focus on the pan-mutant programs, which they believe represent the most compelling opportunity to deliver differentiated therapies across PI3Kα-driven diseases. The upcoming ISSVA World Congress 2026 participation highlights the company's commitment to the vascular anomalies space. Overall, the quarter underscores a capital-efficient shift toward higher-potential assets, with a strong cash position enabling execution through key milestones.